--- title: "Bayer Aktiengesellschaft (ETR:BAYN) Stock Price Down 1.9% - Here's What Happened" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/280563574.md" description: "Bayer Aktiengesellschaft (ETR:BAYN) shares fell by 1.9% during trading on Wednesday, closing at €37.74 after reaching a low of €36.88. Approximately 3.2 million shares were traded, with the stock previously closing at €38.47. The company has a market capitalization of $38.10 billion and operates in pharmaceuticals, consumer health, and crop science. Analysts currently rate Bayer as a Hold, but suggest other stocks may be better investment options." datetime: "2026-03-26T04:07:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280563574.md) - [en](https://longbridge.com/en/news/280563574.md) - [zh-HK](https://longbridge.com/zh-HK/news/280563574.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280563574.md) | [English](https://longbridge.com/en/news/280563574.md) # Bayer Aktiengesellschaft (ETR:BAYN) Stock Price Down 1.9% - Here's What Happened Bayer Aktiengesellschaft (ETR:BAYN - Get Free Report) dropped 1.9% during trading on Wednesday . The company traded as low as €36.88 and last traded at €37.74. Approximately 3,185,697 shares changed hands during trading, The stock had previously closed at €38.47. ## Bayer Aktiengesellschaft Trading Down 1.9% - Best Agriculture Stocks to Buy in 2020 The company has a fifty day moving average of €42.55 and a two-hundred day moving average of €34.88. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 144.30. The stock has a market capitalization of $38.10 billion, a price-to-earnings ratio of -43.30, a price-to-earnings-growth ratio of 36.39 and a beta of 0.93. ## Bayer Aktiengesellschaft Company Profile (Get Free Report) Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. ## Recommended Stories - Five stocks we like better than Bayer Aktiengesellschaft _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Bayer Aktiengesellschaft Right Now? Before you consider Bayer Aktiengesellschaft, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bayer Aktiengesellschaft wasn't on the list. While Bayer Aktiengesellschaft currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### 相關股票 - [Bayer AG (BAYN.DE)](https://longbridge.com/zh-HK/quote/BAYN.DE.md) - [Bayer (BAYRY.US)](https://longbridge.com/zh-HK/quote/BAYRY.US.md) ## 相關資訊與研究 - [Bayer Deepens China Innovation Bet as Pharma Unit Eyes 30% Margin](https://longbridge.com/zh-HK/news/281638616.md) - [Bayer rejigs marketing claims after advertising body challenge](https://longbridge.com/zh-HK/news/281525890.md) - [UK's MHRA approves Bayer's sevabertinib to treat adults with HER2-positive lung cancer](https://longbridge.com/zh-HK/news/281497735.md) - [Bayer Reaffirms Pharma Targets, Aiming for 30% Margin](https://longbridge.com/zh-HK/news/281359378.md) - [UK Regulator OKs Bayer's Treatment for Advanced Non-small Cell Lung Cancer](https://longbridge.com/zh-HK/news/281501722.md)